Cart
sales@molnova.com
Maltitol
CAS No. 585-88-6
Maltitol( —— )
Catalog No. M15155 CAS No. 585-88-6
Maltitol is a sugar alcohol (a polyol) used as a sugar substitute.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | 35 | In Stock |
|
Biological Information
-
Product NameMaltitol
-
NoteResearch use only, not for human use.
-
Brief DescriptionMaltitol is a sugar alcohol (a polyol) used as a sugar substitute.
-
DescriptionMaltitol is a sugar alcohol (a polyol) used as a sugar substitute. It has 75–90% of the sweetness of sucrose (table sugar) and nearly identical properties, except for browning.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number585-88-6
-
Formula Weight344.31
-
Molecular FormulaC12H24O11
-
Purity>98% (HPLC)
-
SolubilitySoluble in Water
-
SMILESC([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@H]([C@@H](CO)O)[C@@H]([C@H](CO)O)O)O)O)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
YRGDS Fibronectin Fr...
This is a fibronectin fragment, an adhesion peptide that displays strong binding affinity to thrombin-stimulated platelets. It is RGD consisting of sequence.
-
Urocortin III, mouse...
Urocortin III, mouse TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III preferentially binds and activates CRF-R2. Urocortin III (Ucn3) is a known component of the behavioral stress response system. Urocortin III and CRF-R2 in the medial amygdala regulate complex social dynamics.
-
3-Epiursolic acid
3-Epiursolic acid may have antiinflammatory activity, it shows inhibition on Cathepsins L (catL), the IC50 value of 6.5 μM, cathepsins L (catL) and B play an important role in tumor progression and have been considered promising therapeutic targets in the development of novel anticancer agents.
